Biomm establishes strategic partnership for the production of insulin glargine.
Agreement with Fiocruz and Gan & Lee provides for ten years of supply to the SUS (Brazilian Public Health System) and reinforces national autonomy in medicines.
247 - Brazilian pharmaceutical company Biomm SA (B3: BIOM3) has signed an initial contract worth R$131 million as part of a ten-year partnership with Gan & Lee Pharmaceuticals of China and Bio-Manguinhos/Fiocruz to supply insulin glargine to the Brazilian Unified Health System (SUS). This information was reported by Brazil Stock Guide.
According to data published on the National Public Procurement Portal (PNCP), the agreement covers the first deliveries scheduled for 2025, partially corresponding to the first year of a broader supply contract. The project is part of a Partnership for Productive Development (PDP), a federal government strategy aimed at nationalizing pharmaceutical production, as per Ordinance No. 59/2024 of SECTICS, Ministry of Health.
The initiative aims to reduce Brazil's dependence on imported insulins and strengthen local technological capacity. According to Biomm, the program should accelerate the replacement of human insulin with insulin glargine, already established as the most widely used basal formulation in the world. The company estimates reaching 30% of the national market in the first year of supply and up to 85% in subsequent years, following the global usage pattern.
“The agreement represents a milestone for both Biomm and the Brazilian public health system,” stated the Chief Financial Officer and Investor Relations Director, Marcelo Safádi Alvares. According to him, the project combines the company's commercial return with priorities of public interest. Biomm also informed that it will continue to update its investors as the implementation schedule progresses.
